focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 265.00
Bid: 260.00
Ask: 270.00
Change: 15.00 (6.00%)
Spread: 10.00 (3.846%)
Open: 253.00
High: 270.00
Low: 255.00
Prev. Close: 250.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Tungsten West 'largest Western tungsten producer'

Mon, 16th Jan 2023 16:26

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Aterian PLC - Morocco-focused metal exploration and development company - Identifies several new high-priority geophysical anomalies at its 100%-owned Agdz copper and silver project. Increases the target area due for further exploration. Chair Charles Bray says: "We are currently working towards building a conceptual geological model for the project, which has already demonstrated some excellent high-grade copper and silver values, up to 26.5% copper and 448 grams per tonne of silver. The presence of multiple historical copper workings at Agdz provides further encouragement, with the project located in an established copper and silver mining district in the eastern Anti-Atlas of Morocco and is an additional exciting exploration opportunity in our Moroccan portfolio."

----------

Quadrise Fuels International PLC - London-based energy solutions provider for a cleaner planet - Says bioMSAR fuel arrived at it client site in Morocco during December. The fuel is currently at Moroccan customs, awaiting final clearance. Expects the remaining logistical issues will be resolved this month so that the trial can then proceed as planned. Expects a successful trial to follow via discussions to conclude a commercial fuel supply agreement in the first half of 2023 as planned. Also announces commercial discussions for licence supply in Utah, US, progressing well, working towards execution of definitive agreements by the first quarter of 2023. Chief Executive Officer Jason Miles says: "Whilst we are frustrated with the delays that we have faced in progressing some of our projects, we remain confident that these will be overcome soon. The team has worked extremely diligently to seek to navigate these challenges such that the impact on the delivery of our projects should be minimal."

----------

Poolbeg Pharma PLC - London-based biopharmaceutical company focusing on infectious diseases - Files patent application to protect use of POLB 001 for new oncology indication. Says scientific finding indicate POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies. Submits a patent application for the use of POLB 001 to treat CRS in CAR T cell patients. Says it is progressing towards trial initiation in 2024. Scientific advisory board member Brendan Buckley says: "By reducing runaway inflammation associated with CRS, POLB 001 has the potential to significantly reduce the serious adverse effects that many CAR T cell patients suffer. With 18 to 19 million cases of cancer diagnosed globally each year, the use of cell therapies is predicted to expand significantly over the coming years with the CAR T cell market expected to grow to an estimated USD6 billion by 2031...we look forward to updating the market as to the progress of this exciting programme."

----------

Coro Energy PLC - Leeds, England-based energy company with a natural gas and clean energy portfolio - Says production from its Italian portfolio continued in line with expectations during the fourth quarter of 2022, following record quarterly revenues in the preceding quarter. Revenue is EUR1.5 million in the fourth quarter, down from EUR2.0 million in the third quarter, and marginally down from EUR1.6 million in the second quarter. Says 1.4 million standard cubic metres of natural gas were produced during the fourth quarter, up from 1.2 million in the third quarter, but down from 1.6 million in the second quarter. Full year 2022 natural gas production is 5.1 million standard cubic metres and revenue is EUR6.0 million. In the week ended January 8, Italian portfolio production averaged 21,091 standard cubic metres per day, up 50% from the 2022 annual average of 13,979 standard cubic metres per day.

----------

Upland Resources Ltd - Malaysia-focused upstream oil and gas company - Believes it is "unequally positioned" in Sarawak, Malaysia, providing the December workflow update on the SK334 joint technical study activity. Says time and resources spent in adding value to the Sarawak SK334 JTS workstream has the potential to generate "significant returns" to shareholders. Chair & Chief Executive Officer Bolhassan Di says: "Block SK334 in Sarawak offers transformational potential for a company our size, sedimentary basins in Sarawak are proven prolific hydrocarbons bearing basins. We are encouraged by the continuing recent discoveries in surrounding blocks...Separately, we also recognise the potential emerging from our UK North Sea P2478 Dunrobin prospect and are working closely with the joint venture partners to realise value there as technical studies complete."

----------

Bradda Head Lithium Ltd - North America-focused lithium development group - Says updated mineral resource estimate at its Basin East project in the US state of Arizona has increased by 17%, alongside a 22% increase in tonnes contained lithium carbonate equivalent, based on "only" 1,200 metres of drilling. Says the 2022 drilling programme has given the company "great confidence" in the estimate at Basin East. Chief Executive Officer Charles FitzRoy says: "2023 is going to be an exciting year of resource growth for Bradda Head. With more drilling already planned at Basin East Extension and Basin North, Bradda Head is excellently placed to take full advantage of the near-term resource growth potential at our sedimentary lithium assets in Arizona."

----------

Tungsten West PLC - Mining company focused on restarting production at the Hemerdon tungsten and tin mine in Devon, England - Says post-tax net present value is GBP297 million with an internal rate of return of 25%. Projects Hemerdon average annual production to be 2,900 tonnes of tungsten trioxide in concentrate and 310 tonnes of tin in concentrate. Says life of mine is 27 years with an an annual average steady-state mining rate of 3.5 megatonnes per annum. Says LOM post financing free cash flow is GBP550 million. Believes feasibility study shows company could be the largest Western tungsten producer. Says GBP12 million of capital expenditure already spent, with remaining capex being GBP31.1 million as of October 1. Executive Vice Chair Mark Thompson says: "The feasibility study provides solutions to the energy price challenges and will enable increased operating efficiencies at the project...Tungsten is on both the EU and US lists of critical metals and due to geopolitical tensions and security of supply issues the market remains strong. With Hemerdon in production, we will provide an alternative source of tungsten to Western consumers in markets which are otherwise dominated by China."

----------

ICG-Longbow Senior Secured UK Property Debt Investments Ltd - Guernsey-based investment company with a portfolio of UK real estate debt investments - Receives remaining GBP6.5 million balance of its LBS loan alongside GBP300,000 in interest and fees, following a refinancing of the underlying property. Says the repayment allows the company to continue its programme of capital distributions to shareholders.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical company focusing on difficult-to-treat cancers and inflammation via precision immunotherapy - Reports encouraging additional data for bexmarilimab for the treatment of hematological malignancies. Says it provoked objective responses in 3 out of 5 patients doesed in the first doublet cohort of the phase 1 and 2 Bexmab study. Says study showed rapid enrolment in doublet and triplet combinations. "The additional BEXMAB data indicates that bexmarilimab contributed to positive responses in the refractory setting where patients failed standard of care," says Chief Medical Officer Marie-Louise Fjallskog. "We are excited about the initial promising results and look forward to gathering additional clinical data for more robust read-outs."

----------

ACP Energy PLC - Lutterworth, England-based company looking for value-accretive opportunities in the oil and gas industry - Says shares are suspended as it signs a sale and purchase agreement for an equity interest being sold by Vinncler CA. Vinncler own the producing assets of a "highly prolific" basin in Latin America currently producing around 4,100 barrels per day, says ACP Energy. Says the proposed acquisition is in line with ACP Energy's stated strategy of identifying and acquiring hydrocarbon producing assets that are either in production or near to production. Says the proposed acquisition, if completed, will constitute a reverse takeover.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Nov 2022 19:49

TRADING UPDATES: Joules nomad resigns; Pharma C loss narrows

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
31 Oct 2022 19:58

TRADING UPDATES: 4Global wins deal; James Cropper profit warning

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
14 Oct 2022 11:14

Faron Pharmaceuticals shares down as raises EUR8.4 million in placing

(Alliance News) - Faron Pharmaceuticals Ltd shares declined on Friday, after it said it has raised EUR8.4 million from a share placing.

Read more
13 Oct 2022 21:17

TRADING UPDATES: Bidstack names new COO; Fintel expands deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 12:10

REPEAT: Faron Pharma half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widened, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
25 Aug 2022 11:43

Faron Pharmaceuticals half-year loss widens on higher R&D spending

(Alliance News) - Faron Pharmaceuticals Ltd on Thursday said its interim loss widen, as the company reported higher research and administrative expenses and remained revenue-less.

Read more
18 Aug 2022 16:02

UK earnings, trading statements calendar - next 7 days

Friday 19 August 
Apax Global Alpha LtdHalf Year Results
Kingspan Group PLCHalf Year Results
Newcrest Mining LtdFull Year Results
Monday 22 August 
Smoove PLCFull Year Results
Tuesday 23 August 
Aferian PLCHalf Year Results
John Wood Group PLCHalf Year Results
Wednesday 24 August 
Costain Group PLCHalf Year Results
Lookers PLCHalf Year Results
Standard Chartered PLCHalf Year Results
Thursday 25 August 
Amigo Holdings PLCQ1 Results
Anglo Pacific Group PLCHalf Year Results
Benchmark Holdings PLCQ3 Results
CRH PLCHalf Year Results
Faron Pharmaceuticals LtdHalf Year Results
Grafton Group PLCHalf Year Results
Harbour Energy PLCHalf Year Results
Hays PLCFull Year Results
Hunting PLCHalf Year Results
Macfarlane Group PLCHalf Year Results
Morses Club PLCFull Year Results
South32 LtdFull Year Results
  
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
30 Jun 2022 15:59

UK shareholder meetings calendar - next 7 days

Friday 1 July 
All Star Minerals PLCGM re name change to Marula Mining
Monday 4 July 
Active Energy Group PLCAGM
Clean Invest Africa PLCAGM
Securities Trust of Scotland PLCAGM
Tuesday 5 July 
Immediate Acquisition PLCAGM
Marks & Spencer Group PLCAGM
Open Orphan PLCAGM
Saga PLCAGM
Smartspace Software PLCAGM
Young & Co's Brewery PLCAGM
Wednesday 6 July 
Assura PLCAGM
ContourGlobal PLCGM re acquisition by KKR
GSK PLCGM re Consumer Healthcare demerger, Haleon listing
Mining Minerals & Metals PLCAGM
PCF Group PLCGM re director allotment authority
Puma Alpha VCT PLCAGM
Shires Income PLCAGM
Sirius Real Estate LtdAGM
Strategic Minerals PLCAGM
Worldwide Healthcare Trust PLCAGM
Thursday 7 July 
C&C Group PLCAGM
Distil PLCAGM
Emmerson PLCAGM
Faron Pharmaceuticals LtdGM re issuance of shares
FD Technologies PLCAGM
Great Portland Estates PLCAGM
Greencare Capital PLCAGM
J Sainsbury PLCAGM
JPMorgan European Growth & Income PLCAGM
Land Securities Group PLCAGM
Likewise Group PLCGM re approval of waiver by takeover/merger panel
N Brown Group PLCAGM
Octopus Apollo VCT PLCAGM
Peel Hunt LtdAGM
Pets At Home Group PLCAGM
Puma VCT 13 PLCAGM
Severn Trent PLCAGM
TomCo Energy PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
28 Jun 2022 18:03

IN BRIEF: Faron raises EUR5 million for bexmarilimab development

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Conducts private placing to raise EUR5 million in 2.0 million newly issued treasury shares at EUR2.49 each. Once the funds are received, Faron expects to have sufficient working capital to last until the first quarter of 2023. Net proceeds will be largely used for the acceleration of the clinical development program and manufacturing of bexmarilimab, its immunotherapy asset.

Read more
15 Jun 2022 19:24

IN BRIEF: Faron Pharma reveals topline results from MATINS trial

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Announces top-line overall survival results from its phase 1/2 'Macrophage Antibody To Inhibit Immune Suppression study, which investigated the safety and efficacy of bexmarilimab monotherapy in ten different hard-to-treat or on operable solid tumour cohorts.

Read more
8 Jun 2022 16:54

IN BRIEF: Faron Pharma doses first patient in bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Doses first patient in the phase I/II BEXMAB study. The study is investigating bexmarilimab, Faron's wholly-owned precision immunotherapy asset, in combination with azacitidine in multiple hematological malignancies. This marks the first time bexmarilimab is being assessed as part of a clinical study in hematologic malignancies, Faron explains.

Read more
16 May 2022 17:35

IN BRIEF: US and Finland approve Faron's bexmarilimab study

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Apr 2022 19:30

IN BRIEF: Faron Pharmaceuticals CEO buys shares worth EUR71,000

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - Chief Executive Markku Jalkanen buys 25,000 shares at an average price of EUR2.82, worth EUR70,533, on Tuesday.

Read more
5 Apr 2022 20:45

TRADING UPDATES: Rambler ups production; SRT Marine anticipates loss

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.